Skip to main content

10 Result(s)

within Axel Grothey Remove this filter Colorectal Surgery Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Defizite in der Behandlung von Patienten mit kolorektalem Karzinom in Deutschland

    Seit etwa 10 Jahren existieren Konsensusempfehlungen zur adjuvanten Therapie des lokal fortgeschrittenen kolorektalen Karzinoms (amerikanisches National Institute of Health 1990, Deutsche Krebsgesellschaft 199...

    Axel Grothey, Lenka Kellermann, Prof. Dr. Hans-Joachim Schmoll in coloproctology (2002)

  2. No Access

    Article

    Should bevacizumab be continued beyond progression in colorectal cancer?

    Medical therapy for advanced colorectal cancer has seen significant changes over the past decade. Most recently, molecular targeted agents such as antibodies against the epidermal growth factor receptor and th...

    Axel Grothey, Dirk Arnold, Lee M. Ellis in Current Colorectal Cancer Reports (2008)

  3. No Access

    Article

    Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial

    Axel Grothey in Current Colorectal Cancer Reports (2009)

  4. No Access

    Article

    Strategies for Managing Chemotherapy-Induced Sensory Neuropathy

    Chemotherapy-induced sensory neuropathy occurs in most patients undergoing treatment with oxaliplatin for colorectal cancer. Although the acute form of neurotoxicity is transient, the chronic form, which is co...

    Joleen Hubbard, Axel Grothey in Current Colorectal Cancer Reports (2010)

  5. No Access

    Article

    Reduced Chemotherapy Duration: A Good Idea?

    Over the past three decades, survival outcomes of high-risk stage II and stage III colon cancer have improved with the use of adjuvant chemotherapy. Oxaliplatin and fluoropyrimidine combination regimens, given...

    Joleen Hubbard, Axel Grothey in Current Colorectal Cancer Reports (2011)

  6. No Access

    Article

    Optimal Treatment Strategies for Localized and Advanced Microsatellite Instability–High Colorectal Cancer

    The defective mismatch repair phenotype (MMR-D) has been recognized as a distinct form of colorectal cancers with specific clinical and biologic features. It is caused by a lack of expression of mismatch repai...

    Axel Grothey in Current Colorectal Cancer Reports (2012)

  7. Article

    Open Access

    The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status

    The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration was established to prospectively combine and analyze data from several randomized trials conducted around the world to answer...

    Thierry André, Timothy Iveson, Roberto Labianca… in Current Colorectal Cancer Reports (2013)

    Download PDF (181 KB) View Article

  8. No Access

    Article

    Distinctive Tumor Biology of MSI-High Colorectal Cancer

    High-frequency microsatellite instability (MSI-H) accounts for roughly 15 % of all cases of colorectal cancer (CRC) and results from pathogenic mutations or epigenetic changes in mismatch repair (MMR) proteins...

    Neil Majithia, Benjamin R. Kipp, Axel Grothey in Current Colorectal Cancer Reports (2015)

  9. No Access

    Article

    New Adjuvant Trial Designs in Colon Cancer

    The treatment of colon cancer has evolved significantly since the discovery of 5-fluorouracil, and with continued innovation, it will continue to advance for the foreseeable future. In this review, we identify...

    Alexis D. Leal, Joleen Hubbard, Daniel Sargent… in Current Colorectal Cancer Reports (2015)

  10. No Access

    Article

    Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers

    The application of advanced genomic testing to develop tumor-specific molecular profiles is essential to facilitating precision medicine pharmacotherapy. These approaches are highly relevant in colorectal canc...

    May Cho, Ryan Beechinor, Sepideh Gholami, Axel Grothey in Current Colorectal Cancer Reports (2021)